| Molecular Formula | C17H21N3O |
| Molar Mass | 283.37 |
| Density | 1.135±0.06 g/cm3(Predicted) |
| Boling Point | 498.6±45.0 °C(Predicted) |
| Solubility | Soluble in DMSO (up to 5 mg/ml) or in Ethanol (up to 5 mg/ml with warming) |
| Appearance | powder |
| Color | white to beige |
| pKa | 15.01±0.70(Predicted) |
| Storage Condition | 2-8°C |
| Stability | Stable for 2 years as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| Physical and Chemical Properties | Bioactive Atglistatin is a highly selective inhibitor of adipose triglyceride lipase (ATGL) with an IC50 of 0.7 μm. |
| Target | IC50: 0.7 μM (ATGL) |
| In vitro study | Atglistatin inhibits lipolysis in cell and organ culture by targeting ATGL and is not cytotoxic at concentrations up to 50 μm. |
| In vivo study | In vivo, Atglistatin (I. p.) dose-and time-dependently inhibited lipolysis. Oral treatment with Atglistatin resulted in dose-dependent reductions in FA and glycerol of up to 50% and 62%, respectively, and also resulted in a significant reduction in plasma TG levels (43%). In addition, Atglistatin showed significant tissue distribution, mainly accumulated in the liver and adipose tissue. |
| Hazard Symbols | Xn - Harmful![]() |
| Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | 36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 3.529 ml | 17.645 ml | 35.29 ml |
| 5 mM | 0.706 ml | 3.529 ml | 7.058 ml |
| 10 mM | 0.353 ml | 1.764 ml | 3.529 ml |
| 5 mM | 0.071 ml | 0.353 ml | 0.706 ml |